Human VEGFR3/Flt-4 Antibody

Catalog # Availability Size / Price Qty
AF349
AF349-SP
VEGF R3/Flt‑4 in Human Cervical Squamous Metaplasia.
1 Image
Product Details
Citations (12)
FAQs
Supplemental Products
Reviews

Human VEGFR3/Flt-4 Antibody Summary

Species Reactivity
Human
Specificity
Detects human VEGF R3 in direct ELISAs and Western blots. In Western blots, approximately 15% cross-reactivity with recombinant mouse VEGF R3 is observed and less than 2% cross-reactivity with recombinant human VEGF R1 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant human VEGF R3
Tyr25-Ile776
Accession # P35916
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4)
Immunohistochemistry
5-15 µg/mL
See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Immunohistochemistry VEGF R3/Flt‑4 in Human Cervical Squamous Metaplasia. View Larger

VEGF R3/Flt‑4 in Human Cervical Squamous Metaplasia. VEGF R3/Flt‑4 was detected in immersion fixed paraffin-embedded sections of human cervical squamous metaplasia using Human VEGF R3/Flt‑4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF349) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR3/Flt-4

VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

VEGF R3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGF R3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). VEGF R3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGF R3 may be important for lymph angiogenesis.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 3
Entrez Gene IDs
2324 (Human); 14257 (Mouse)
Alternate Names
EC 2.7.10; EC 2.7.10.1; FLT4; Flt-4; fms-related tyrosine kinase 4; LMPH1A; PCLFLT41; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; Tyrosine-protein kinase receptor FLT4; vascular endothelial growth factor receptor 3; VEGF R3; VEGFR3; VEGFR-3; VEGFR3Fms-like tyrosine kinase 4

Product Datasheets

Citations for Human VEGFR3/Flt-4 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

12 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling
    Authors: K Heinolaine, S Karaman, G D'Amico, T Tammela, R Sormunen, L Eklund, K Alitalo, G Zarkada
    Circ. Res, 2017;0(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  2. Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4
    Authors: LD Volk-Drape, KL Hall, AC Wilber, S Ran
    PLoS ONE, 2017;12(6):e0179257.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. TGF-?1 Is Present at High Levels in Wound Fluid from Breast Cancer Patients Immediately Post-Surgery, and Is Not Increased by Intraoperative Radiation Therapy (IORT)
    PLoS ONE, 2016;11(9):e0162221.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  4. Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance
    Authors: Masaaki Miyazawa
    J. Exp. Med., 2016;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  5. Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction
    Authors: Tom J Parry
    Eur. J. Pharmacol, 2016;796(0):76-89.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Western Blot
  6. Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
    Authors: Wakisaka N, Hasegawa Y, Yoshimoto S, Miura K, Shiotani A, Yokoyama J, Sugasawa M, Moriyama-Kita M, Endo K, Yoshizaki T
    PLoS ONE, 2015;10(12):e0144056.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  7. Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma.
    Authors: Omoto, Itaru, Matsumoto, Masataka, Okumura, Hiroshi, Uchikado, Yasuto, Setoyama, Tetsuro, Kita, Yoshiaki, Owaki, Tetsuhir, Kijima, Yuko, Shinchi, Hiroyuki, Ishigami, Sumiya, Ueno, Shinichi, Natsugoe, Shoji
    Oncol Lett, 2014;7(4):1027-1032.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  8. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
    Authors: Thelen A, Scholz A, Benckert C, Von Marschall Z, Schroder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S
    Int. J. Cancer, 2008;122(11):2471-81.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  9. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.
    Authors: Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E
    Leuk. Res., 2004;28(3):243-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  10. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.
    Authors: Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, Wei LH, Yang PC, Kuo ML
    Cancer Res., 2004;64(2):554-64.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  11. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.
    Authors: Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS
    Int. J. Cancer, 2003;104(5):603-10.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  12. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
    Authors: Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, Sato S, Mizunuma H, Smith SK
    Clin. Cancer Res., 2003;9(4):1361-9.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Cell and Tissue Staining Kits

Immunohistochemistry Reagents

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human VEGFR3/Flt-4 Antibody

There are currently no reviews for this product. Be the first to review Human VEGFR3/Flt-4 Antibody and earn rewards!

Have you used Human VEGFR3/Flt-4 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review